RNS Number:8443E
Inion Oy
20 June 2006



     Inion Appoints Dr Mike Goekbora as Senior Director Product Development



Tampere, Finland and Takeley, UK. 20 June 2006...Inion (LSE: IIN.L), a Finnish
company focused on the development of novel biodegradable medical implants, is
pleased to announce that Dr Mike Goekbora has been appointed as Senior Director
Product Development and will be responsible for planning and controlling Inion's
product development activities and processes. Dr Goekbora will report to Dr Kirk
Andriano, Vice President of R&D and will be based in Tampere, Finland.



Dr Goekbora has spent the last 13 years working in the orthopaedics and medical
devices field and is an experienced R&D professional with expertise in (bio)
polymers and an excellent track record in product development. Most recently, he
was Senior Research Engineer for Stryker Orthopaedics, a leading worldwide,
medical products and services company, where he gained substantial experience in
all aspects of the medical device industry operations and made a major
contribution to product development with alpha-hydroxypolyester
bioresorbable polymers for pediatry, craniomaxillofacial, spine, trauma,
shoulder and knee implants.



Commenting on Dr Goekbora's appointment, Dr Auvo Kaikkonen, Inion CEO said: "We
are very pleased to welcome Mike to the team. His strong product development
experience in the orthopaedics industry, combined with his hands-on technical
expertise and project leadership skills will ensure that he plays a key role in
the development of Inion's products and a valuable contribution to our business.
"



Dr Mike Goekbora commented, "While working at Stryker Orthopaedics I was a great
admirer of Inion's range of biodegradable products and I am delighted that I am
now in a position to play a leading role in their future development."



                                     -Ends-



For further information, please contact:




Inion Oy

Dr Auvo Kaikkonen, Chief Executive Officer             Tel: +358 3 230 6600
                                                       Tel: +44 (0)1279 874 222


Citigate Dewe Rogerson                                 Tel: +44 (0)207 638 9571
Mark Swallow / David Dible / Helena Podd






About Inion (www.inion.com)

Inion Oy is a Finnish company that specializes in the development of
biodegradable medical implants.



The Inion core expertise and technology lies in the design and manufacture of
innovative biodegradable plates, screws, pins and membranes that are used to
enhance the healing of skeletal injuries (bone and soft tissue), such as those
caused by trauma or by reconstructive surgery. Inion implants are made from its
proprietary Inion OptimaTM family of biomaterials, with properties tailored for
specific surgical applications, in terms of strength, flexibility and rate of
degradation.



Inion has developed and launched products in five strategic business areas -
cranio-maxillofacial surgery, orthopaedic trauma, sports medicine, dental
surgery and most recently in the spinal implant area - in nearly 50 countries
worldwide.



Inion was incorporated in early 2000 by an international team of experts in
biodegradable materials and their clinical applications, and listed on the
Official List of the UK Listing Authority in December 2004. The Company's has
operations in the UK, R&D and production facilities in Tampere, Finland, and a
US office in Oklahoma City, OK.



This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions
or the negative thereof. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or achievements of the
Group to be materially different from future results, performance or
achievements expressed or implied by such forward-looking statements. Such
forward-looking statements are based on numerous assumptions regarding the
Group's present and future business strategies and the environment in which the
Group will operate in the future. Among the important factors that could cause
the Group's actual results, performance or achievements to differ materially
from those in forward-looking statements include those relating to Inion's
funding requirements, regulatory approvals, reliance on third parties,
intellectual property, key personnel and other factors. These forward-looking
statements speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained in this announcement to reflect any
change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result
of these factors, prospective investors are cautioned not to rely on any
forward-looking statement.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAEAXKNFAKKEFE
Inion Oy (LSE:IIN)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Inion Oy Charts.
Inion Oy (LSE:IIN)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Inion Oy Charts.